Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide

OBJECTIVE: Isocitrate dehydrogenase (IDH)-wildtype glioblastomas are the most malignant glial tumours. Median survival is only 14–16 months after diagnosis, with patients aged ≥ 65 years reportedly showing worse outcome. This study aimed to further evaluate the prognostic role of age in a homogenous...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Kerstin, Turowski, Bernd, Felsberg, Jörg, Malzkorn, Bastian, Reifenberger, Guido, Steiger, Hans-Jakob, Budach, Wilfried, Haussmann, Jan, Knipps, Johannes, Rapp, Marion, Hänggi, Daniel, Sabel, Michael, Mijderwijk, Hendrik-Jan, Kamp, Marcel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810639/
https://www.ncbi.nlm.nih.gov/pubmed/32748120
http://dx.doi.org/10.1007/s00432-020-03334-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810639/
https://www.ncbi.nlm.nih.gov/pubmed/32748120
http://dx.doi.org/10.1007/s00432-020-03334-3

Ejemplares similares